6 completed, 1 recruiting. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Eye Pain: new trials by email Literature Review of Eye Pain trials Research Report on Eye Pain
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP) SAF312 Placebo, SAF312 - Chronic Ocular Pain | Phase 2 | Completed | Novartis Pharmaceuticals | 153 | 2021-04-21 | 2024-10-09 |
| Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER) Clemastine, Placebo - Optic Neuritis | Phase 2 | Recruiting | University of California, San Francisco | 90 | 2017-02-28 | 2026-03-11 |
| Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery SAF312, Placebo - Postoperative Ocular Pain After PRK Surgery | Phase 2 | Completed | Novartis Pharmaceuticals | 40 | 2016-12-01 | 2021-10-06 |
| Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome | Phase 2 | Completed | Sylentis, S.A. | 66 | 2015-06-01 | 2016-04-05 |
| RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1% - Corneal Endothelial Cell Loss, Ocular Pain | Phase 2 | Completed | Biogen | 307 | 2014-05-31 | 2025-06-03 |
| RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%, Placebo - Inflammation and Pain Following Ocular Surgery | Phase 2 | Completed | Biogen | 109 | 2014-02-28 | 2025-06-03 |
| Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Sylentis, S.A. | 60 | 2012-11-01 | 2015-05-25 |
Dry Eye Syndromes (2) · Corneal Endothelial Cell Loss (1) · Endophthalmitis (1) · Inflammation (1) · Multiple Sclerosis (1) · Optic Neuritis (1) · Vision Disorders (1)
Eye Diseases (7) · Eye Manifestations (7) · Neurologic Manifestations (7) · Pain (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Lacrimal Apparatus Diseases (2) · Pathologic Processes (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Corneal Diseases (1) · Cranial Nerve Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Eye Infections (1)
Clemastine (1) · Lubricant Eye Drops (1) · omaveloxolone (1)
Biogen (2) · Novartis Pharmaceuticals (2) · Sylentis, S.A. (2) · University of California, San Francisco (1)
United States (5) · Spain (2) · Estonia (1) · Japan (1) · United Kingdom (1)